Aa
A Potent HBsAg Response to Treatment of HBeAg-positive Chronic hepatitis B with Interferon alpha plus a nucleos(t)ide analogue, 38out of 142 cured
http://archive.mail-list.com/hbv_research/message/20111129.004409.4561d88b.en.html
Beijing You'an Hosipital, Capital Medical University, PR China.
Abstract
Background and aims: HBsAg clearance is the closest cure outcome in hepatitis B. The goal of this study is to investigate clinical features in chronic hepatitis B patients achieving seroconversion of HBsAg after treatment with interferon alpha and a nucleos(t)ide analogue. Methods: This retrospective study enrolled thirty-eight chronic hepatitis B patients treated with interferon alpha plus a nucleos(t)ide analogue and achieved HBsAg seroconversion during the period from June 2001 to May 2009. Clinical and laboratory data of the patients were collected before and after treatment every 3 months. All patients with HBsAg seroconversion in this study were followed up at least 12 months post-treatment. Results: 38 out of 142 patients achieved HBsAg sercovertion after treatment with interferon alpha and a nucleos(t)tid analogue for prolonged period of time(medium 31 months). The median time to HBeAg seroconversion and to HBsAg seroconversion was 19.5 months (range 3-60 months) and 25.5 months (range 9-63 months) respectively. Thirty-six patients (95%) sustained HBsAg seroconversion during the post-treatment follow-up. Three different HBsAg response patterns were observed with classical model accounting for 57.9% (22/38 cases), simultaneous transition mode accounting for 23.7% (9/38 cases), and HBsAg prior transition model accounting for 18.4% (7/38 cases). Conclusions: Extended treatment with interferon alpha in combination with a nucleos(t)ide analogue in patients with HBeAg-positive appears to be a promising approach for achieving high rate of HBsAg clearance - the closest outcome to cure.
Beijing You'an Hosipital, Capital Medical University, PR China.
Abstract
Background and aims: HBsAg clearance is the closest cure outcome in hepatitis B. The goal of this study is to investigate clinical features in chronic hepatitis B patients achieving seroconversion of HBsAg after treatment with interferon alpha and a nucleos(t)ide analogue. Methods: This retrospective study enrolled thirty-eight chronic hepatitis B patients treated with interferon alpha plus a nucleos(t)ide analogue and achieved HBsAg seroconversion during the period from June 2001 to May 2009. Clinical and laboratory data of the patients were collected before and after treatment every 3 months. All patients with HBsAg seroconversion in this study were followed up at least 12 months post-treatment. Results: 38 out of 142 patients achieved HBsAg sercovertion after treatment with interferon alpha and a nucleos(t)tid analogue for prolonged period of time(medium 31 months). The median time to HBeAg seroconversion and to HBsAg seroconversion was 19.5 months (range 3-60 months) and 25.5 months (range 9-63 months) respectively. Thirty-six patients (95%) sustained HBsAg seroconversion during the post-treatment follow-up. Three different HBsAg response patterns were observed with classical model accounting for 57.9% (22/38 cases), simultaneous transition mode accounting for 23.7% (9/38 cases), and HBsAg prior transition model accounting for 18.4% (7/38 cases). Conclusions: Extended treatment with interferon alpha in combination with a nucleos(t)ide analogue in patients with HBeAg-positive appears to be a promising approach for achieving high rate of HBsAg clearance - the closest outcome to cure.
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
